The study was a parallel design , randomized trial wherein each 3-month treatment was conducted in a Canadian academic center between March 2011 and September 2012 and involved 141 participants with type 2 diabetes ( HbA1c 6.5 % -8.5 % [ 48-69 mmol/mol ] ) treated with oral antihyperglycemic agents .